Efficacy of olaparib combined with dabrafenib and trametinib for a patient with BRAF mutated and ATM deleted metastatic melanoma

Documenti analoghi

• Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients
  di: Samy Belkaïd, et al.
  Pubblicazione: (2025)
• Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab
  di: Sarah E. Lochrin, et al.
  Pubblicazione: (2024)
• Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion–insertion R) in an advanced non‐small cell lung cancer patient
  di: Akiko Tamura, et al.
  Pubblicazione: (2024)
• Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation
  di: Hiroyuki Karasawa, et al.
  Pubblicazione: (2024)
• A case of BRAF mutation‐positive recurrent ovarian high‐grade serous carcinoma with remarkable response to combined dabrafenib and trametinib therapy
  di: Tatsuhito Furui, et al.
  Pubblicazione: (2025)